Clinical trial of indomethacin in Alzheimer's disease
Jospeh Rogers, Lachlan Kirby, S. R. Hempelman, Donald A. Berry, Patrick L. McGeer, Alfred W. Kaszniak, J. Zalinski, M. Cofield, L. Mansukhani, Peter D. Willson, Frederick J. Kogan · Neurology · 1993
In a 6-month, double-blind, placebo-controlled study, 100 to 150 mg/d indomethacin appeared to protect mild to moderately impaired Alzheimer's disease patients from the degree of cognitive decline exhibited by a well-matched, placebo-treated group. Over a battery of cognitive tests, indomethacin patients improved 1.3% (+/- 1.8%), whereas placebo patients declined 8.4% (+/- 2.3%)--a significant difference (p < 0.003). Caveats include adverse reactions to indomethacin and the limited scale of the trial.